Study Progresses to Fourth Higher 90 mg/m2Dose CohortCompelling Patient Response Highlighted by Stable Disease and Significant Reduction in Blast ...

Bio-Path (BPTH) provided an update from the company’s ongoing Phase 1/1b clinical trial evaluating BP1002 for the treatment of ...

Venetoclax, a selective Bcl-2 inhibitor, has proven effective in chronic lymphocytic leukemia (CLL), but genetic mutations or ...

Researchers determined discontinuing BTK inhibitors appears to be more common than discontinuing venetoclax plus obinutuzumab for older patients with CLL.

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Ascentage Pharma’s U.S. IPO will support clinical testing of its two lead drugs, small molecules in development for advanced cases of certain blood cancers.

A new research paper titled "ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells" has been published in Oncotarget. ABT199 ...

Research found that ibrutinib reduces red blood cell aggregation in patients with chronic lymphocytic leukemia (CLL), while obinutuzumab/venetoclax does not significantly alter blood viscosity.